Leman Biotech has recently received extensive evaluations from renowned institutions and companies in the Guangdong, Hong Kong, Macao, and Greater Bay Area. Notable entities such as Guangdong Hengjian Investment Holdings Limited, Hong Kong Cyberport, top PE BPEA EQT, Zhuhai Zhengling Venture Capital, Zhuhai Zhengfang Group, and Xiangxue Pharmaceutical have assessed Leman Biotech's core technology, R&D progress, talent team, and development plans.

On March 8, 2023, Leman Biotech was invited to participate in the EPFL Engineering Industry Day at the Swiss Federal Institute of Technology in Lausanne (EPFL). This event, which was interrupted for three years due to the Covid-19 epidemic, is finally back at the Swiss Science and Technology Conference Center this year. The event aims to showcase the research and innovation capabilities of the EPFL School of Engineering, its collaboration with the industry, and the transfer of research technology, as well as its social impact.

In a recent report by Labiotech.eu, the renowned online media focusing on the European biotechnology industry, Leman Biologics has been recognized as one of the 13 exceptional biotech companies in Switzerland's "Health Valley." The report highlights Leman Biologics' groundbreaking work in developing the metabolic regulator protein IL-10-Fc, which enhances the effectiveness of existing immunotherapy treatments like CAR-T by boosting T-cell metabolism.

SWI swissinfo.ch recently highlighted Leman Biotech in research development of cancer immunotherapy in Switzerland. The article focuses on the innovative research conducted by Professor Li Tang, co-founder of Leman Biotech, and his research team, Laboratory of Biomaterials for Immunoengineering. The research aims at overcoming T-cell exhaustion and improving the efficacy of current immunotherapies. The article sheds light on Leman Biotech's cutting-edge approach and its potential to revolutionize cancer treatment.

On February 24, 2023, the "Innovation China" Innovative and Entrepreneurial Investment Conference was successfully held in Shenzhen Futian Convention and Exhibition Center. During the ceremony, the "National Top 100" and the "Biomedical Industry Top 5" were announced.

Dr. Youjia Li, the Director of Research and Development at Leman Biotech, was invited to participate in the prestigious 2023 Guangzhou Cell Therapy Summit held on February 15-16. During the conference, Dr. Li delivered a keynote speech and engaged in insightful discussions with fellow experts on the development, challenges, and solutions in the field of immune cell therapy.

Leman Biotech has been granted approval from the First Affiliated Hospital of University of Science and Technology of China to conduct an Investigator-Initiated Trial (IIT) clinical study of Meta10-19 injection for the treatment of relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) (NCT05715606). The company has now announced the recruitment of patients for this study.

Leman Biotech and the team led by professor Xingbing Wang, Director of the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), reached a clinical trial cooperation agreement on "Clinical Trial Study on the Safety and Efficacy of Metabolism-enhanced CD19 CAR-T Cell Injection in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma". The two parties have formally signed a cooperation agreement to establish a clinical project partnership and jointly promote multi-center IIT clinical research of metabolism-enhanced CAR-T cell therapy.